Pacylex Pharmaceuticals Reports Phase 1 Safety and Efficacy Results for Zelenirstat in Colorectal and other Cancers
Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex's lead product candidate, in refractory/ relapsed colorectal and other cancers, will be presented January 20, 2024, at the upcoming ASCO Gastrointestinal Cancers Symposium.
- Today Pacylex announced that the results of its Phase 1 dose escalation safety and tolerability study for zelenirstat, an investigational NMT inhibitor and Pacylex's lead product candidate, in refractory/ relapsed colorectal and other cancers, will be presented January 20, 2024, at the upcoming ASCO Gastrointestinal Cancers Symposium.
- Pacylex presents zelenirstat results in gastrointestinal and other cancer patients at the ASCO Gastrointestinal Cancers Symposium on January 18-20, 2024, in San Francisco, CA.
- Zelenirstat prolonged progression free survival in gastrointestinal and other cancer patients in Phase 1 at the recommended Phase 2 dose.
- An advanced colorectal cancer patient relapsed from 7 prior lines of therapy, has seen reductions of approximately 50% in CEA and tumor volumes so far with zelenirstat.